



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

17 December 2015
EMA/849940/2015
EMA/H/W/000673

Public statement

Lamivudine/Zidovudine ViiV

Cessation of manufacture

GlaxoSmithKline Research & Development Ltd has informed the European Medicine Agency (EMA) of its decision to stop the manufacture of the HIV medicine Lamivudine/Zidovudine ViiV for commercial reasons.

Lamivudine ViiV was evaluated by EMA under the Article 58 provision,¹ whereby EMA's Committee for Medicinal Products for Human Use (CHMP), in cooperation with the World Health organization (WHO), gives scientific opinions on medicines intended for use outside the EU.

The CHMP gave a positive opinion on Lamivudine/Zidovudine ViiV in November 2005.

Following the decision of GlaxoSmithKline Research & Development Ltd, Lamivudine/Zidovudine ViiV will no longer be available in the non-EU countries where it was authorised and the CHMP will not make further recommendations on its conditions of use.

Patients and healthcare professionals who have questions about alternative treatments should contact authorities in their country.

The European Public Assessment Report (EPAR) for Lamivudine/Zidovudine ViiV will be updated to indicate that the medicine is no longer available.

¹ Regulation (EC) No 726/2004

